86 related articles for article (PubMed ID: 36906459)
41. mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders.
Franz DN; Capal JK
Orphanet J Rare Dis; 2017 Mar; 12(1):51. PubMed ID: 28288694
[TBL] [Abstract][Full Text] [Related]
42. New insights into a spectrum of developmental malformations related to mTOR dysregulations: challenges and perspectives.
Mühlebner A; Bongaarts A; Sarnat HB; Scholl T; Aronica E
J Anat; 2019 Sep; 235(3):521-542. PubMed ID: 30901081
[TBL] [Abstract][Full Text] [Related]
43. mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis.
Citraro R; Leo A; Constanti A; Russo E; De Sarro G
Pharmacol Res; 2016 May; 107():333-343. PubMed ID: 27049136
[TBL] [Abstract][Full Text] [Related]
44. Perfect match: mTOR inhibitors and tuberous sclerosis complex.
Luo C; Ye WR; Shi W; Yin P; Chen C; He YB; Chen MF; Zu XB; Cai Y
Orphanet J Rare Dis; 2022 Mar; 17(1):106. PubMed ID: 35246210
[TBL] [Abstract][Full Text] [Related]
45. mTOR pathway: Insights into an established pathway for brain mosaicism in epilepsy.
Gerasimenko A; Baldassari S; Baulac S
Neurobiol Dis; 2023 Jun; 182():106144. PubMed ID: 37149062
[TBL] [Abstract][Full Text] [Related]
46. mTOR dysregulation and tuberous sclerosis-related epilepsy.
Curatolo P; Moavero R; van Scheppingen J; Aronica E
Expert Rev Neurother; 2018 Mar; 18(3):185-201. PubMed ID: 29338461
[TBL] [Abstract][Full Text] [Related]
47. Mammalian target of rapamycin (mTOR) activation in focal cortical dysplasia and related focal cortical malformations.
Wong M
Exp Neurol; 2013 Jun; 244():22-6. PubMed ID: 22015915
[TBL] [Abstract][Full Text] [Related]
48. Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies.
Wong M
Epilepsia; 2010 Jan; 51(1):27-36. PubMed ID: 19817806
[TBL] [Abstract][Full Text] [Related]
49. Is mTOR inhibition a systemic treatment for tuberous sclerosis?
Moavero R; Coniglio A; Garaci F; Curatolo P
Ital J Pediatr; 2013 Sep; 39():57. PubMed ID: 24044547
[TBL] [Abstract][Full Text] [Related]
50. Review: Mechanistic target of rapamycin (mTOR) pathway, focal cortical dysplasia and epilepsy.
Marsan E; Baulac S
Neuropathol Appl Neurobiol; 2018 Feb; 44(1):6-17. PubMed ID: 29359340
[TBL] [Abstract][Full Text] [Related]
51. Cortical Dysplasia and the mTOR Pathway: How the Study of Human Brain Tissue Has Led to Insights into Epileptogenesis.
Lee WS; Baldassari S; Stephenson SEM; Lockhart PJ; Baulac S; Leventer RJ
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163267
[TBL] [Abstract][Full Text] [Related]
52. mTOR Inhibitors in Children: Current Indications and Future Directions in Neurology.
Jeong A; Wong M
Curr Neurol Neurosci Rep; 2016 Dec; 16(12):102. PubMed ID: 27815691
[TBL] [Abstract][Full Text] [Related]
53. Focal malformations of cortical development: new vistas for molecular pathogenesis.
Lim KC; Crino PB
Neuroscience; 2013 Nov; 252():262-76. PubMed ID: 23892008
[TBL] [Abstract][Full Text] [Related]
54. Advances in the mTOR signaling pathway and its inhibitor rapamycin in epilepsy.
Zhao W; Xie C; Zhang X; Liu J; Liu J; Xia Z
Brain Behav; 2023 Jun; 13(6):e2995. PubMed ID: 37221133
[TBL] [Abstract][Full Text] [Related]
55. Hemimegalencephaly and tuberous sclerosis complex: A rare yet challenging association.
Sidira C; Vargiami E; Dragoumi P; Zafeiriou DI
Eur J Paediatr Neurol; 2021 Jan; 30():58-65. PubMed ID: 33387903
[TBL] [Abstract][Full Text] [Related]
56. mTOR inhibitors as a new therapeutic option for epilepsy.
Curatolo P; Moavero R
Expert Rev Neurother; 2013 Jun; 13(6):627-38. PubMed ID: 23739000
[TBL] [Abstract][Full Text] [Related]
57. The Putative Role of mTOR Inhibitors in Non-tuberous Sclerosis Complex-Related Epilepsy.
Goldstein HE; Hauptman JS
Front Neurol; 2021; 12():639319. PubMed ID: 33643212
[TBL] [Abstract][Full Text] [Related]
58. A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits.
Feliciano DM; Lin TV; Hartman NW; Bartley CM; Kubera C; Hsieh L; Lafourcade C; O'Keefe RA; Bordey A
Int J Dev Neurosci; 2013 Nov; 31(7):667-78. PubMed ID: 23485365
[TBL] [Abstract][Full Text] [Related]
59. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.
Franz DN
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1181-92. PubMed ID: 21916571
[TBL] [Abstract][Full Text] [Related]
60. The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: Current evidence and future perspectives.
Schubert-Bast S; Rosenow F; Klein KM; Reif PS; Kieslich M; Strzelczyk A
Epilepsy Behav; 2019 Feb; 91():94-98. PubMed ID: 29941212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
